新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 组学 » 糖尿病药物可能改善阿尔兹海默症患者的大脑活力

糖尿病药物可能改善阿尔兹海默症患者的大脑活力

来源:生物谷 2016-05-05 17:58

2016年4月28日讯/生物谷BIOON/丹麦研究人员公布了一项发现,显示了糖尿病药物利拉鲁肽对阿尔茨海默氏症患者的临床试验结果。

试点研究发表在今天的《Aging Neuroscience》杂志上,表明用利拉鲁肽治疗可以帮助阿尔茨海默氏症患者延缓大脑迟钝,但该药并没有显示出在临床试验期对阿尔茨海默氏症蛋白质淀粉样蛋白或对记忆和思维所起的作用。

研究者对38名阿尔茨海默病患者实施了为期26周的临床试验,分别用利拉鲁肽或安慰剂进行治疗。参与者在治疗前后通过脑部扫描来测量淀粉样蛋白水平以及扫描测量大脑活动的标志——葡萄糖代谢。志愿者也在实验前后进行了记忆力测试。

脑部蛋白质扫描结果显示,处理组服用该药的志愿者大脑中淀粉样蛋白含量增加,这样的结果与安慰剂组一样。此外,研究人员称,相比安慰剂,通过测试记忆和思维性能,该药没有体现出明显的功效。尽管如此,服用利拉鲁肽显示了大脑中葡萄糖的消耗程度,这表明在服用药物期间大脑活动维持在一个较高的水平。

英国老年痴呆症研究中心的研究主任Simon Ridley博士说:

“糖尿病和阿尔茨海默病之间存在一种固定的联系,先前的小鼠研究表明利拉鲁肽会潜在性限制阿尔茨海默氏症大脑的损伤。这个有关阿尔滋海默症患者的治疗药物利拉鲁肽的临床试验显示了该药物对大脑活动的好处,但对阿尔兹海默症大脑蛋白质的标志水平或记忆力不产生影响。”

“当前治疗阿尔茨海默氏症的医药比较有限,在英国约有五十万人患有这种疾病,我们迫切需要找到一种治疗方法来阻止或减缓大脑中造成的损失。目前在英国有一个更大的利拉鲁肽实验,我们希望该研究将进一步揭示这种药物用于治疗阿尔茨海默氏症的潜在用途。”(生物谷Bioon.com)

本文系生物谷原创编译整理,欢迎转载!点击 获取授权 。更多资讯请下载生物谷APP.

生物谷推荐阅读:

Diabetes drug could influence brain activity in Alzheimer's

Researchers in Denmark have released findings from a small clinical trial of the diabetes drug liraglutide in people living with Alzheimer's disease. The pilot study published today in the journal Frontiers in Aging Neuroscience suggests that treatment with liraglutide could help to limit the loss of brain activity that can be seen in Alzheimer's disease, but did not show benefits against the build-up of the Alzheimer's protein amyloid or an effect on memory and thinking over the trial period.

The 26-week trial followed 38 people with Alzheimer's disease who received either liraglutide or a placebo treatment. Participants had brain scans before and after treatment to measure levels of the amyloid protein as well as scans measuring glucose metabolism – a marker of brain activity that normally declines as Alzheimer's progresses. The volunteers also had memory tests before and after the trial. The results from the amyloid brain scans showed that levels of the protein increased in the brain in people taking the drug as well as the placebo. The researchers also report that the drug did not show measurable benefits on memory and thinking test performance compared to the placebo.

Despite this, those taking liraglutide showed a less marked decline in the use of glucose in the brain suggesting that brain activity was maintained to a higher level in those taking the drug. Dr Simon Ridley, Director of Research at Alzheimer's Research UK, said: "There is a well-established link between diabetes and Alzheimer's disease and previous research in mice indicated that liraglutide could hold potential in limiting the damaging effects of Alzheimer's in the brain. This small clinical trial of liraglutide in people living with Alzheimer's, shows some benefit of the drug on brain activity but does not show an impact on memory or on levels of a hallmark Alzheimer's protein in the brain.

The real test of such a drug being used to treat Alzheimer's will be whether larger trials are able to show a measurable benefit to a person's symptoms and quality of life. "Current treatments for Alzheimer's are limited and with half a million people living with the disease in the UK, we urgently need to find treatments that can stop or slow the damage it causes in the brain. There is a larger trial of liraglutide currently underway here in the UK and we hope that study will shed more light on the potential of this drug as a treatment for Alzheimer's."
 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库